The Mexico vaccine market was valued at USD 2.21 Billion in 2024, driven by the robust government immunization programs and innovations in vaccine technology in the region. The market is anticipated to grow at a CAGR of 5.30% during the forecast period of 2025-2034, with the values likely to reach USD 3.70 Billion by 2034.
Merck & Co.
Merck has a strong presence in the Mexico vaccine market. It delivers high-quality vaccines and supports evidence-based health initiatives. Merck's HPV vaccine is widely used to reduce cervical cancer rates, particularly through school-based immunization programs. The company collaborates with Mexican researchers and institutions to strengthen local clinical trial networks.
This product will be delivered within 3-5 business days.
Mexico Vaccine Market Overview
In Mexico, the vaccine market is witnessing significant growth, driven by the rising disease prevalence and increased government and private sector investment in immunization infrastructure. National programs, such as the National Vaccination Campaign against Influenza and COVID-19 (2024-2025), play a substantial role in boosting vaccine uptake, especially among vulnerable populations. Moreover, the increasing collaboration between government agencies and pharmaceutical companies is leading to improved vaccine delivery and storage, which is projected to positively impact the market dynamics.Mexico Vaccine Market Growth Drivers
Rising Vaccine-Preventable Disease Incidence to Boost Market Growth
The increasing prevalence of infectious diseases is a major driver for the vaccine market in Mexico. It is reported that the country faces a significant burden from vaccine-preventable diseases. According to the World Health Organization (WHO), Mexico recorded 333,980 deaths from communicable, maternal, perinatal, and nutritional conditions in 2021, with 19,469 deaths attributed to infectious and parasitic diseases. Respiratory infections accounted for 292,606 deaths, as per the WHO Mortality Database. This rising disease incidence, especially among vulnerable groups such as the elderly and individuals with chronic conditions, is expected to augment the market demand in the coming years.Mexico Vaccine Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:Robust Regulatory Support
In September 2024, Mexico's Federal Commission for the Protection against Sanitary Risks (Cofepris) approved the Jynneos vaccine for use against Mpox in adults aged 18 and over. The vaccine is specifically intended for individuals at high risk of exposure and is not recommended for the general public, including children, pregnant women, or those who are breastfeeding. This regulatory approval reflects Mexico’s proactive public health strategy and is expected to contribute positively to the Mexico vaccine market growth.Increasing Vaccination Campaigns
One of the key market trends is the rise in large-scale vaccination campaigns aimed at expanding vaccine coverage. For instance, the Ministry of Health’s (SSA) National Vaccination Campaign against Influenza and COVID-19 is set to run from October 15, 2024, to March 28, 2025, in Mexico. To achieve this, the SSA plans to distribute over 36 million doses of the influenza vaccine and about 23 million COVID-19 vaccine doses. Such public health initiatives are anticipated to elevate the Mexico vaccine market value in the forecast period.Mexico Vaccine Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Product Type
- Multivalent Vaccines
- Monovalent Vaccines
Market Breakup by Type
- Subunit Vaccines
- Recombinant vaccines
- Conjugate Vaccines
- Toxoid vaccines
- Inactivated
- Live Attenuated
- mRNA vaccines
- Viral vector vaccines
Market Breakup by Route of Administration
- Oral
- Parenteral
- Nasal
Market Breakup by Disease Indication
- Viral Diseases
- Hepatitis
- Influenza
- HPV
- MMR
- Rotavirus
- Herpes Zoster
- COVID-19
- Others
- Bacterial Vaccines
- Meningococcal Diseases
- Pneumococcal diseases
- DPT
- Others
- Cancer Vaccines
- Allergy Vaccines
Market Breakup by Age
- Pediatric
- Adult
Market Breakup by End User
- Hospital Pharmacies
- Retail Pharmacies
- Government Suppliers
- Others
Mexico Vaccine Market Share
Segmentation by Product Type Set to Hold High Market Value
Based on the product type, the vaccine market in Mexico is segmented into multivalent and monovalent vaccines. The multivalent vaccine segment is likely to hold a dominant market share owing to its efficiency, cost-effectiveness, and ease of administration. These vaccines reduce the number of injections needed, improving compliance, especially in pediatric and elderly populations. Multivalent vaccines such as the DTP (diphtheria, tetanus, pertussis), MMR (measles, mumps, rubella), and pentavalent vaccines are widely administered as part of the National Immunization Program in the country.Mexico Vaccine Market Analysis by Region
In Mexico, the market dynamics vary significantly across different regions, influenced by factors such as healthcare infrastructure, population density, and public health initiatives. The central region, including Mexico City and Estado de México, is expected to lead the market share, owing to the high population density, advanced healthcare infrastructure, and the presence of key government health institutions. Additionally, high vaccination coverage in this region is driven by robust public health campaigns, including seasonal vaccinations like flu and COVID-19.Leading Players in the Mexico Vaccine Market
The key features of the market report comprise patent analysis, clinical trials analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:GlaxoSmithKline plc
GSK is a key player in advancing immunization coverage across Mexico, particularly through its focus on public-private partnerships and community-level health initiatives. The company supports Mexico’s vaccination goals by introducing next-generation vaccines. GSK is also actively involved in educational outreach, working alongside healthcare providers to boost awareness around preventable diseases.Merck & Co.
Merck has a strong presence in the Mexico vaccine market. It delivers high-quality vaccines and supports evidence-based health initiatives. Merck's HPV vaccine is widely used to reduce cervical cancer rates, particularly through school-based immunization programs. The company collaborates with Mexican researchers and institutions to strengthen local clinical trial networks.
Sanofi
Sanofi is known for playing a prominent role in making immunization more inclusive and accessible throughout Mexico. The company works closely with public health agencies to improve childhood vaccination rates in both urban and remote regions. Sanofi also actively contributes to pandemic preparedness by supporting influenza surveillance systems in Mexico.Pfizer Inc
Pfizer Inc., a global biopharmaceutical company, supports nationwide immunization strategies with its pneumococcal and meningococcal vaccines. The company collaborates with healthcare professionals to train staff in vaccine administration and improve cold chain logistics. To support equitable access, Pfizer partners with local and regional health authorities to facilitate distribution outreach programs and mobile vaccination units.Other key players in the market include AstraZeneca plc and Johnson & Johnson Services, Inc
Key Questions Answered in the Mexico Vaccine Market Report
- What was the Mexico vaccine market value in 2024?
- What is the Mexico vaccine market forecast outlook for 2025-2034?
- What is the market segmentation based on product type?
- What is the market segmentation based on type?
- What is the market breakup based on the route of administration?
- What is the market breakup by disease indication?
- What is the market breakup by age?
- What is the market breakup by end user?
- What major factors aid the Mexico vaccine market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the major drivers, opportunities, and restraints in the market?
- What are the major trends influencing the market?
- Who are the key players involved in the Mexico vaccine market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Vaccine Market Overview
4 Mexico Vaccine Market Landscape*
5 Mexico Vaccine Market Dynamics
6 Mexico Vaccine Market Segmentation (218-2034)
8 Patent Analysis
9 Clinical Trials Analysis
10 Funding and Investment Analysis
11 Strategic Initiatives
12 Supplier Landscape
13 Mexico Vaccine Market - Distribution Model (Additional Insight)
Companies Mentioned
- GlaxoSmithKline plc
- Merck & Co.
- Sanofi
- Pfizer Inc.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 250 |
Published | June 2025 |
Forecast Period | 2025 - 2034 |
Estimated Market Value ( USD | $ 2.21 Billion |
Forecasted Market Value ( USD | $ 3.7 Billion |
Compound Annual Growth Rate | 5.3% |
Regions Covered | Mexico |
No. of Companies Mentioned | 4 |